A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Phase 3

Completed

Brief Summary: A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo. This study is accepting male and female participants between 18 -65 years old who have been diagnosed with schizophrenia. This study will be conducted in 60 locations world wide. The study will last up to nine (9) weeks.

Detailed Description: This is a multicenter, randomized, double-blind, parallel-group, fixed-dosed study evaluating the efficacy and safety of two doses of SEP-363856 (75 and 100 mg/day) versus placebo over a 6-week Treatment Period in acutely psychotic subjects with schizophrenia. This study is projected to randomize approximately 462 subjects to 3 treatment groups (SEP-363856 75 mg/day, SEP-363856 100 mg/day, or placebo) in a 1:1:1 ratio. Treatment assignment will be stratified by country. Study drug will be taken once a day and may be taken with or without food.

This study is designed to test the hypotheses that treatment with SEP-363856 in adult subjects with schizophrenia will result in significantly greater reduction (i.e. improvement) in PANSS total score and CGI-S score at Week 6 from Baseline when compared to placebo. The overall Type I error is controlled for two hierarchical families of hypotheses. The first family includes hypotheses about the testing of change from Baseline in PANSS total score at Week 6 between each of the SEP-363856 dose levels vs. placebo. The second family of hypotheses are about the testing of change from Baseline in CGI-S score at Week 6 between each of the SEP-363856 dose levels vs. placebo.

Recruitment & Eligibility

Inclusion Criteria

Male or female subject between 18 to 65 years of age (inclusive) at the time of consent.
Subject must give written informed consent and privacy authorization prior to participation in the study; adolescents must also provide informed assent.
Subject meets DSM-5 criteria for schizophrenia as established by clinical interview at screeing.
Subject must have a CGI-S score ≥ 4
Subject must have a PANSS total score ≥ 80 and a PANSS item score ≥ 4 on 2 or more of the following PANSS items: delusions, conceptual disorganization, hallucinations, and unusual thought content
Subject has an acute exacerbation of psychotic symptoms (persisting no longer than 2 months prior to providing informed consent).
Subject has marked deterioration of functioning in one or more areas.
Subject is, in the opinion of the Investigator, generally healthy based on screening medical history, PE, neurological examination, vital signs, ECG and clinical laboratory values.

Exclusion Criteria

Subject has a DSM-5 diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, or lifetime history of significant substance abuse that, in the opinion of the Investigator or Sponsor, may have had a significant and potentially permanent impact on the brain or other body systems, major depressive disorder, bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder, and posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms are not the primary focus of treatment.
Subject is at significant risk of harming self, others, or objects based on Investigator's judgment.
Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study
Female subject who is pregnant or lactating
Subject has any clinically significant abnormal laboratory value(s) at Screening as determined by investigator.

Arm && Interventions

Primary Outcome Measures

Name	Time	Method
Change from Baseline in Positive and negative syndrome scale (PANSS) total score at Endpoint (Week 6)	Baseline and Week 6	PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.

Secondary Outcome Measures

Name	Time	Method
Change from Baseline in Clinical Global Impressions - Severity (CGI-S) score at Endpoint (Week 6)	Baseline and Week 6	The CGI-S is a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.

Locations (61): Woodland Research Northwest
🇺🇸
Rogers, Arkansas, United States
Advanced Research Center, Inc.
🇺🇸
Anaheim, California, United States
Clinical Innovations, Inc.
🇺🇸
Bellflower, California, United States
ProScience Research Group
🇺🇸
Culver City, California, United States
Collaborative Neuroscience Network
🇺🇸
Long Beach, California, United States
California Neuropsychopharmacology Clinical Research Institute
🇺🇸
San Diego, California, United States
Schuster Medical Research Institute
🇺🇸
Sherman Oaks, California, United States
Larkin Behavioral Health Services
🇺🇸
Hollywood, Florida, United States
South Florida Research Phase I-IV, INC.
🇺🇸
Miami Springs, Florida, United States
Atlanta Center for Medical Research
🇺🇸
Atlanta, Georgia, United States
Scroll for more (51 remaining)
Woodland Research Northwest
🇺🇸Rogers, Arkansas, United States